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Abstract
Background: Recent work demonstrated that the gait of people with mild cognitive impairment (MCI) differs from that of age-matched 
controls and, in general, that walking ability, as measured in the clinic, does not necessarily reflect actual, daily performance. We evaluated if 
the quantity and quality of everyday walking (ie, community ambulation) differs in older adults with MCI, compared to age-matched controls.
Methods: Inclusion criteria included: age 65–90 years, able to walk at least 5 minutes unassisted, and ≥2 falls in the past 6 months. Subjects 
with MCI were included if they scored 0.5 on the Clinical Dementia Rating Scale. To assess stepping quantity and quality, subjects wore a tri-
axial accelerometer on the lower-back for 7 days.
Results: Age and gender were similar (p > .10) in MCI (n = 36, 77.8 ± 6.4 years; 27.8% men) and controls (n = 100, 76.0 ± 6.2 years; 22.0% 
men). As expected, Montreal Cognitive Assessment scores were lower (p < .001) in MCI (21.31 ± 4.05), compared to controls (25.81 ± 2.64). 
Walking time was lower (p = .016) in MCI (0.74 ± 0.48 hours/d), compared to controls (1.05 ± 0.66 hours/d). Within-bout walking (eg, stride 
regularity) was less consistent (p = .024) in MCI (0.51 ± 0.14), compared to controls (0.58 ± 0.14). Changes in stride regularity across bouts 
were lower (p < .001) in MCI (0.13 ± 0.04), compared to controls (0.17 ± 0.01).
Conclusions: Older adults with MCI walk less and with a more variable within-bout and less variable across-bout walking pattern, as 
compared to cognitively-intact subjects matched with respect to age and gender. These findings extend previous clinical work and suggest that 
MCI affects both the quantity and quality of community ambulation.
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Cognitive deficits are the hallmark of mild cognitive impairment 
(MCI), a translational state between normal aging and dementia. 
Nonetheless, balance, gait, and mobility are also altered in older 
adults with MCI (1,2). Compared to controls, gait speed is reduced 
and gait variability is increased in older adults with MCI (3–5). 
In addition, gait apparently helps to predict cognitive decline and 
dementia (5–10), underscoring the relationship between motor and 
cognitive function in aging. While there is some indication that daily 
physical activity is also altered in MCI and that these changes may 
assist with the prediction of cognitive decline (11), little is known 
about the everyday, community ambulation stepping patterns of 
older adults with MCI.
Recent work demonstrated that the one-time assessment of gait and 
mobility in the clinic, that is, mobility capacity, is only modestly correlated 
with daily life mobility function (12–16). At the same time, measures of 
daily life mobility function may help to capture risk of falls and neuro-
degeneration that are not reflected in a conventional, one-time clinical 
assessment of mobility (14–16). Based on these reports, we speculated 
that the everyday stepping pattern, that is, mobility function, might also 
be affected by MCI. In this exploratory study, we addressed the follow-
ing questions: (i) Is the amount of daily-living walking different in older 
adults with MCI and age-matched controls? (ii) Is the quality of the walk-
ing pattern different in older adults with MCI and controls? and (iii) Is 
everyday walking mobility related to performance on clinical tests of gait 
and balance?
Methods
Participants
The present analysis is based on the baseline assessment of sub-
jects who participated in a randomized controlled trial designed 
to reduce fall rates in older adults (17,18). Briefly, older adults at 
five clinical centers across five countries (Belgium, Israel, Italy, the 
Netherlands, and United Kingdom) were studied. Subjects were 
included if they were: (i) aged 65–90 years, (ii) self-report ability 
to walk at least 5 minutes unassisted, (iii) on stable medications, 
and (iv) had at least 2 falls in the previous 6 months, a requirement 
of the parent study, the RCT. Subjects with MCI were included if 
they scored 0.5 on the Clinical Dementia Rating Scale. Subjects 
were excluded if they had other significant comorbidities or clini-
cal diagnosis of dementia or severe cognitive impairment. For 
example, subjects were excluded if they had psychiatric comor-
bidity (eg, major depressive disorder as determined by DSM IV 
criteria), clinical diagnosis of dementia or other severe cognitive 
impairment, history of stroke, traumatic brain injury, Parkinson’s 
disease, or other neurological disorders (other than MCI, for that 
group), acute lower back or lower extremity pain, peripheral neu-
ropathy, rheumatic and orthopaedic diseases, or if they had an 
unstable medical condition including cardiovascular instability in 
the past 6 months. In addition, to avoid complications due to wear 
time of the accelerometer, we only included subjects with 7-day 
recordings. The study was approved by each clinical site’s ethics 
committee. All participants provided informed written consent 
prior to testing.
Demographics and Lab-Based Measures
Age and sex were recorded for each participant along with other 
subject characteristics. The Montreal Cognitive Assessment 
(MOCA) evaluated general cognitive function and subitems were 
used to estimate visualspatial/executive function and attention. Gait 
speed, stride length, and stride time variability were measured during 
usual walking and the SF-36 was used to evaluate general health 
and physical function (17). The Short Physical Performance Battery 
(SPPB), the 2-minute walk test, Mini-Balance Evaluation Systems 
Test (MINIBEST), and the Four Square Step Test (FSST) assessed dif-
ferent aspects of balance, gait and mobility capacity in the lab (17).
Everyday Walking Data Collection
At the end of the laboratory testing session, participants wore 
a water-proof, tri-axial accelerometer (Axivity AX3, York, UK; 
23.0 × 32.5 × 7.6 mm; weight: 11 g; 100 Hz sampling rate) for 1 
week. The accelerometer was placed on the fifth lumbar vertebrae, 
held in place with a hydrogel adhesive, and covered with a Hypafix 
bandage. Participants were asked to continue their activities as usual. 
Upon completion of the recording, participants removed the device 
and sent it back to the local clinical site.
As previously described, we identified each bout of walking 
(as well as lying, standing, and sitting) throughout the week-long 
recording and then extracted measures that reflect the quantity and 
quality of walking (14,15). To focus on steady-state walking and to 
compare in-lab walking with community ambulation, we focused 
on bouts that were at least 60 seconds long (14,15). To evaluate the 
quality of the walking pattern, we extracted the step regularity and 
the peak value of the Fourier transformed acceleration in the vertical 
direction in each bout (14,15); for both metrics, higher values reflect 
greater walking consistency. These measures can be determined 
without the need to identify individual steps and are related to the 
known increase in gait variability in MCI. Each subject’s median 
value over the week was determined. In addition, to assess bout-to-
bout variations over the week, we calculated the standard deviation 
(SD) of these two measures of walking quality for each subject.
Statistical Analysis
Normality of data was tested with a Shapiro-Wilk test. Descriptive 
statistics are reported as means and SD. Spearman’s correlations 
assessed the relationship between measures and multiple regression 
analyses evaluated the effect of covariates and the independence of 
measures. For the within-bout and across-bout measures of com-
munity ambulation walking quality, we used a Bonferonni corrected 
cutoff of p = .025 to define the level of significance; otherwise, a 
two-tailed p-value less than .05 was considered statistically signifi-
cant. Cohen’s d was used to estimate effect sizes of group differ-
ences. Statistical analyses were performed using SPSS Version 22 
(SPSS Inc.).
Results
Age, sex, height, weight, body mass index, and general health were 
similar in the two groups (Table 1). As expected, MOCA scores were 
lower in the MCI group. Measures of gait and mobility capacity, that 
is, when tested in the lab, were worse or tended to be worse in the 
subjects with MCI, compared to the controls (Table 2).
Figure 1A shows an example of the bar code summary of the 
walking bouts and other conditions recorded in an example sub-
ject with MCI and a control subject. As seen in this example, on a 
group level, the MCI group spent less time walking, as compared to 
the controls (see Table 3). Figure 1B–D shows an example walking 
bout of a subject with MCI and a control subject, along with the 
corresponding autocorrelation plot and frequency domain analyses. 
Stride time regularity and the peak in the frequency domain were 
lower in the subject with MCI, as compared to the control subject. 
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Similar results were seen on a group level (see Table 3). Within bout 
walking consistency, as measured by both stride regularity and the 
peak in the frequency domain, were significantly lower in the MCI 
subjects than in the controls. For both measures of stepping quality, 
the across bout variability was lower in the subjects with MCI, com-
pared to the controls (see Table 3).
The correlations between the mobility capacity and mobility 
function measures were generally modest to moderate (see Figure 
2), suggesting that the mobility function measures captured differ-
ent aspects of mobility than the in-lab, one-time measures. This 
possibility was also explored using multiple regression analyses. 
When included in the same regression model, measures of mobility 
capacity and mobility function were both independently associ-
ated with group assignment (ie, MCI vs controls). For example, 
the Four Square Step Test (p = .025) and the SD of the peak ampli-
tude (p = .005) were both related to group (ie, MCI vs controls). 
Finally, we explored if the observed group differences in everyday 
stepping were related to cognitive function. When MOCA scores 
were added to the regression models, several of the group differ-
ences in everyday walking were no longer significant (see Table 
3), suggesting that cognitive function may have influenced or 
mediated the across group changes in everyday stepping. We also 
explored if MCI subtype (amnestic vs nonamnestic) might impact 
the stepping measures by dividing the subjects into those who 
scored above or below the MCI group’s median value (and into a 
tertile split, comparing the worst and best groups) for visualspa-
tial/executive and attention sub-scores. There were no differences 
in the everyday walking pattern between these subgroups both for 
the visualspatial/executive items and the attention items on the 
MOCA (p > .47).
Discussion
Consistent with previous findings (1–5), we observed that older 
adults with MCI performed poorer on in-lab measures of balance, 
gait and mobility than age-matched older adults who did not have 
MCI or dementia. Here, we find that not only is mobility capacity 
altered, but mobility function, as reflected in daily life ambulation, 
is also changed in MCI. Everyday stepping quantity and stepping 
quality were reduced in MCI, compared to age-matched controls. In 
addition, mobility capacity and mobility function were only mod-
erately related to each other (recall Figure 2), similar to findings 
in other cohorts (12–16). We also found that measures of mobil-
ity capacity and function were independently associated with group 
assignment. Taken together, these results suggest that measures of 
everyday walking reflect aspects of mobility that are not simply a 
mirror-image of the gait and balance changes measured in the lab 
setting. Interestingly, while MCI is conventionally defined by a lack 
of impact of the cognitive changes on activities of daily living, the 
present findings suggest that subtle, but measurable changes in eve-
ryday ambulation can be detected in MCI.
Several hypotheses putatively explain the association between 
gait changes, as measured in the lab, and cognitive impairment in 
older adults, in MCI, and in dementia (1–5). Some suggest that the 
relationship is simply a manifestation of changes in brain areas com-
mon to both the control of walking and to cognitive functioning. For 
example, reduced grey and white matter volumes and white matter 
hyper-intensities are observed in brain regions that contribute to gait 
dysfunction and to cognitive deficits. There is, however, increasing 
evidence that gait in aging relies on specific, higher-level cognitive 
functioning and that deficits in these brain regions (eg, dorsal lateral 
Table 1. Subject Characteristics
Controls (n = 100) MCI (n = 36) p Value
Age (years) 76.0 ± 6.2 77.8 ± 6.4 .145
Gender (% men) 22.0% 27.8% .506
Education (years) 13.4 ± 3.9 10.9 ± 2.9 <.001
Height (m) 1.65 ± 0.01 1.64 ± 0.08 .897
Weight (kg) 70.5 ± 13.4 70.9 ± 13.9 .883
Body mass index (kg/m2) 25.9 ± 4.2 26.2 ± 4.6 .787
Montreal Cognitive Assessment: Total score 25.8 ± 2.6 21.3 ± 4.1 <.001
Montreal Cognitive Assessment: visuospatial/executive score 4.13 ± 0.1 3.11 ± 0.21 <.00001
Montreal Cognitive Assessment: Attention score 5.65 ± 0.6 4.89 ± 0.21 <.001
Number of falls (in past 6 months) 2.96 ± 2.14 2.08 ± 0.68 .166
SF-36 General Health 62.12 ± 1.94 57.90 ± 3.48 .143
SF-36 Total Physical Health 62.97 ± 1.73 58.71 ± 3.04 .221
SF-36 Physical Function 67.75 ± 2.38 60.15 ± 4.28 .188
Note: MCI = Mild cognitive impairment.
Table 2. In-Lab Measures of Gait and Mobility Capacity
Controls (n = 100) MCI (n = 36) p Value Effect Size
Gait speed (m/s) 1.06 ± 0.24 0.90 ± 0.29 .017 0.601
Stride Length (m) 1.16 ± 0.20 1.02 ± 0.22 .004 0.666
Stride time variability (%) 2.24 ± 1.92 2.78 ± 2.35 .117 0.252
Short Physical Performance Battery 9.42 ± 2.03 8.44 ± 2.74 .070 0.406
Mini Best test of balance (MiniBest) 23.0 ± 5.87 19.8 ± 6.4 .008 0.521
Two min walk distance (m) 133.1 ± 32.0 118.2 ± 33.1 .019 0.457
Four Square Step Test (s) 11.2 ± 5.1 15.7 ± 10.1 .002 0.562
Note: MCI = Mild cognitive impairment.
Journals of Gerontology: MEDICAL SCIENCES, 2017, Vol. 00, No. 00 3
Downloaded from https://academic.oup.com/biomedgerontology/advance-article-abstract/doi/10.1093/gerona/glx187/4372278
by K U Leuven user
on 26 January 2018
pre-frontal cortex) contribute to the gait changes seen in MCI and 
dementia (7,19). The present work was not designed to probe mech-
anisms. Still, we found that changes in everyday (within-bout) walk-
ing consistency were no longer significant in models that adjusted 
for MOCA scores and that the everyday walking measures were 
only moderately correlated with in-lab measures. These findings sug-
gest that brain regions and networks related to cognitive function 
are likely involved in the observed changes in daily walking and, 
further, that the specific mechanisms that contribute to changes in 
community ambulation are not identical to those that contribute to 
the changes quantified in the lab-setting. Perhaps other factors that 
were not measured (eg, affect) explain these findings. Future work is 
needed to assess this question.
The present study has several limitations. For example, we used the 
Clinical Dementia Rating Scale to identify subjects with MCI, while 
other criteria are available. Our use of this definition may impact gen-
eralizability. In the future, it will be interesting to see if the observed 
findings are affected by the exact definition of MCI and if the results 
vary with MCI-subtype (eg, amnestic vs nonamnestic). In explora-
tory analyses, when the MCI subjects were divided into those with 
relatively better or worse visualspatial/executive function or attention, 
there were no differences in everyday walking, suggesting that the 
results may be insensitive to MCI type. Still, a larger sample and other 
ways of characterizing subjects as amnestic or nonamnestic should be 
investigated in the future. Because subjects in the present study were 
recruited to participate in a falls intervention study, all of the subjects 
Table 3. Measures of Mobility Function Derived From the 7-day Recordings
Controls (n = 100) MCI (n = 36) p Value Effect Size
Walking quantity Time spent walking (hours/day)  
(from walking bouts ≥ 60 s)
1.05 ± 0.66 0.74 ± 0.48 .016b 0.537
Within Bout Walking Quality Stride Regularity (unitless) 0.58 ± 0.14 0.51 ± 0.14 .024 0.500
Peak amplitude (g2/Hz) 0.72 ± 0.21 0.62 ± 0.21 .015 0.476
Across Bout Variability of Walking 
Quality
SD of stride regularity (unitless) 0.17 ± 0.01 0.13 ± 0.04 <.001a,b,c 1.372
SD of peak amplitude (g2/Hz) 0.18 ± 0.01 0.12 ± 0.05 <.001a,b,c 1.664
Note: MCI = Mild cognitive impairment; SD = Standard deviation.
a,b,cGroup differences persisted after adjusting for the MOCA total score (or the visuospatial/executive score or attention score; all 3 MOCA scores behaved 
similarly), years of education and 2-min walk distance (a proxy for cardiovasvular function), respectively.
Figure 1. Example steps in the processing of the 7-day accelerometer data for a subject with MCI and a control subject. (A) Barcode plot illustrating daily activity 
for 1 day; (B) Raw vertical acceleration signal in one bout of walking; (C) Autocorrelation plot used to determine stride regularity in a bout; (D) Frequency domain 
plot used to determine the peak in the frequency domain for a bout of walking. MCI = Mild cognitive impairment. Please see the online version for a color figure.
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had a history of multiple falls. While this history was controlled for 
in that subjects in both groups met this criteria, and falls are common 
in MCI (20), in the future, it will be important to assess whether the 
observed findings generalize to people with MCI who do not have a 
history of falls. The cross-sectional nature of the present analyses also 
needs to be kept in mind. Finally, while we applied previously vali-
dated methods to detect everyday walking (14,15), it is possible that 
other activities may have been identified as walking.
The present findings suggest that everyday stepping quantity and 
stepping quality, both within and across bout metrics, are related to 
MCI and are not strongly related to in-lab measures of gait and bal-
ance. Prospective studies are needed to determine if and how these 
measures of everyday walking can augment the prediction of cogni-
tive decline and the progression to dementia, potentially addressing 
the need for additional markers of future cognitive impairment in 
older adults (7,19,20).
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